Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals Plc is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. Its portfolio consists of preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The firm products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.

The mean of analysts' price targets for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) points to a 127.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know

BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ: CNTA) with a price target of $19 (293% upside), and an Outperform rating. The analyst writes that ZF874 is a differentiated oral therapy as it addresses the root cause of AATD.

BMO Capital Sees Almost 300% Upside On Centessa Stock

New York, New York--(Newsfile Corp. - June 15, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Centessa Pharmaceuticals plc ("Centessa" or the "Company") (NASDAQ: CNTA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Centessa and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Centessa Pharmaceuticals plc - CNTA

Preclinical data showed that single-agent LB101, PD-L1xCD47 LockBody, delivered systemically led to meaningful tumor regressions and was well tolerated Preclinical data showed that single-agent LB101, PD-L1xCD47 LockBody, delivered systemically led to meaningful tumor regressions and was well tolerated

Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting

- Decision based on reassessment of commercial potential of lixivaptan following recent observation of ALT/AST elevations in ALERT Study -

Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

– Company advances innovative rare disease and immuno-oncology portfolio toward ‘4x24' goal of four registrational programs in 2024 –

Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates

BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the appointment of Saurabh Saha, M.D., Ph.D. to its Board of Directors. Dr. Saha is currently the Chief Executive Officer of Centessa Pharmaceuticals plc (Nasdaq:CNTA) (“Centessa”) and brings more than 20 years of biopharmaceutical research and development expertise to the role. “W

Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. to its Board of Directors

– Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones –

Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update

BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim Genomic Medicines & Rare Disease Day on Thursday, March 31, 2022, at 11:00 am Eastern Time.

Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day

BOSTON and LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announced that Antoine Yver, MD, MSc, has been appointed Executive Vice President and Chairman of Development. In this newly created role reporting to the CEO, Dr. Yver will be accountable for the Company's overall development strategy, including scientific, clinical and regulatory matters, and will continue to provide support to research and clinical development teams.

Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise

BOSTON and LONDON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), together with its subsidiary Palladio Biosciences, Inc. (“Palladio”), today announced it has started dosing of the first subject in its pivotal Phase 3 clinical trial (“ACTION Study”) evaluating lixivaptan as a potential treatment for Autosomal Dominant Polycystic Kidney Disease (“ADPKD”). The trial is expected to enroll approximately 1,350 subjects across more than 200 sites in over 20 countries. The Company anticipates completing enrollment in the second half of 2023 and, if results are supportive, plans to submit a New Drug Application (“NDA”) after completion of the one-year double-blind portion of the study.

Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease

~ Initiation of registrational Phase 3 ACTION clinical study with lixivaptan is an important milestone to bring this potential new treatment option to ADPKD patients ~

Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Applicati

BOSTON and LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announced that it has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 20, 2021.

Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index

Longeveron

Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy.

2 Big Stock Bets That Are Insiders Are Buying Now

Centessa Pharmaceuticals (CNTA) has been struggling lately, but the selling pressure may be coming to an end soon.

Centessa Pharmaceuticals (CNTA) Sees Hammer Chart Pattern: Time to Buy?

~ Announced positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B subjects not on prophylaxis, demonstrating 88% reduction in median Annualized Bleeding Rate (“ABR”) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~

Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates

BOSTON and LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA) today announced that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the following investor conferences:

Centessa Pharmaceuticals to Present at Upcoming Conferences in 2021

Centessa Pharmaceuticals plc (NASDAQ: CNTA) announced proof-of-mechanism data from the first three subjects in Phase 1 Part B study of ZF874 in Alpha-1 Antitrypsin Deficiency (AATD).  AATD is an autosomal recessive disorder frequently caused by missense mutations in the A1AT gene.

Why Did Centessa's Shares Plunge 10% Today?

~ First demonstration that a pharmacological chaperone can provide sufficient functional Z-A1AT increases to potentially achieve greater than 11 micromolar levels in individuals with PiZZ genotype ~

Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874

Schrodinger 

NEW YORK & BOSTON & LONDON--(BUSINESS WIRE)--Today, Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger announced a collaboration to discover novel orexin receptor agonists.

Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists

~ New $300 million facility, combined with Company's cash balance as of June 30, 2021, provides access to over $900 million to advance development programs and enable pursuit of strategic business development opportunities ~ ~ New $300 million facility, combined with Company's cash balance as of June 30, 2021, provides access to over $900 million to advance development programs and enable pursuit of strategic business development opportunities ~

Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital

Centessa Pharmaceuticals PLC – ADR (NASDAQ: CNTA), in partnership with its subsidiary ApcinteX Limited announced that results from its ongoing first-in-human proof-of-concept study to analyze SerpinPC in severe hemophilia A and B patients are positive. This news automatically pushed the Pharma stock up by 20% on Thursday morning.

Here's why Centessa Pharma is up 20% on Thursday morning

Centessa Pharmaceuticals plc (NASDAQ: CNTA) has announced positive topline results from the Phase 2a part of AP-0101, the six-month repeat dose portion of the study evaluating SerpinPC in severe hemophilia A and B patients. SerpinPC was well-tolerated.

Centessa Stock Surges On Positive Data From Hemophilia Candidate

~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~

Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis

CAMBRIDGE, Mass. & LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021, beginning at 5:00 p.m. Eastern Time.

News for Centessa Pharmaceuticals PLC Stock (CNTA)